Authors:
BURRIS HA
MOORE MJ
ANDERSEN J
GREEN MR
ROTHENBERG ML
MADIANO MR
CRIPPS MC
PORTENOY RK
STORNIOLO AM
TARASSOFF P
NELSON R
DORR FA
STEPHENS CD
VANHOFF DD
Citation: Ha. Burris et al., IMPROVEMENTS IN SURVIVAL AND CLINICAL BENEFIT WITH GEMCITABINE AS FIRST-LINE THERAPY FOR PATIENTS WITH ADVANCED PANCREAS CANCER - A RANDOMIZED TRIAL, Journal of clinical oncology, 15(6), 1997, pp. 2403-2413
Authors:
FOSSELLA FV
LIPPMAN SM
SHIN DM
TARASSOFF P
CALAYAGJUNG M
PEREZSOLER R
LEE JS
MURPHY WK
GLISSON B
RIVERA E
HONG WK
Citation: Fv. Fossella et al., MAXIMUM-TOLERATED DOSE DEFINED FOR SINGLE-AGENT GEMCITABINE - A PHASE-I DOSE-ESCALATION STUDY IN CHEMOTHERAPY-NAIVE PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG-CANCER, Journal of clinical oncology, 15(1), 1997, pp. 310-316
Citation: R. Nelson et P. Tarassoff, DYSPNEA WITH GEMCITABINE IS COMMONLY SEEN, OFTEN DISEASE-RELATED, TRANSIENT, AND RARELY SEVERE, European journal of cancer, 31A, 1995, pp. 950-950